Clinical Trial Detail

NCT ID NCT02676986
Title Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Queen Mary University of London
Indications

triple-receptor negative breast cancer

estrogen-receptor positive breast cancer

Therapies

Enzalutamide + Exemestane

Exemestane

Enzalutamide

Age Groups: adult senior

No variant requirements are available.